Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia – Final Appraisal Document
In DRAFT guidance venetoclax plus obinutuzumab is recommended for untreated chronic lymphocytic leukaemia if there is a 17p deletion or TP53 mutation, or where there is no mutation and fludarabine plus cyclophosphamide and rituximab or bendamustine plus rituximab is unsuitable.
Source:
National Institute for Health and Care Excellence
SPS commentary:
Additionally venetoclax plus obinutuzumab is recommended for use within the Cancer Drugs Fund as an option for untreated chronic lymphocytic leukaemia, only if there is no 17p deletion or TP53 mutation, and FCR or BR is suitable.